Вход на сайт

Просмотр новости

Найдите то, что Вас интересует

DELTA Equity Partners Closes Technology And Health Fund II At €125 Million Hard Cap

Дата публикации: 14-07-2026 19:28:06

DELTA Equity Partners announced the first and final close of DELTA Equity Partners Technology & Health Fund II Coöperatief U.A. at its €125 million hard cap.
The post DELTA Equity Partners Closes Technology And Health Fund II At €125 Million Hard Cap appeared first on Pulse 2.0.


Основное содержимое страницы с новостью.

DELTA Equity Partners announced the first and final close of DELTA Equity Partners Technology & Health Fund II Coöperatief U.A. at its €125 million hard cap.

The Amsterdam-based private equity investor closed Fund II within four months. DELTA said the fund was significantly oversubscribed, reflecting strong support from both existing and new investors.

Almost all investors in DELTA’s first fund participated in Fund II. The firm also added a select group of new institutional investors to its investor base.

Fund II will continue the same strategy as DELTA’s first fund, investing in growing SME companies in the technology and health sectors. The firm focuses on supporting entrepreneurs and management teams through strategic buy-and-build initiatives.

DELTA provides portfolio companies with capital, knowledge, experience, and access to its network. The firm said Fund II will allow it to continue backing companies that are positioned to build leading businesses in attractive markets.

The fund close enables DELTA to build on the foundation established by Fund I. The firm said it will remain focused on creating value for portfolio companies, fellow shareholders, and investors.

DELTA also emphasized that it will continue supporting companies that contribute positively to society through technology, digitalization, healthcare, and health-related services.

The firm expects to announce the first Fund II investments soon. DELTA said its organization and infrastructure have developed further, allowing it to execute its strategy more efficiently.

Founded in 2021, DELTA Equity Partners is an independent private equity investor based in Amsterdam. The firm specializes in strategic buy-and-build strategies for SME companies in the technology and health sectors.

KEY QUOTES:

“We are grateful for the continued trust of our investors. The strong level of support from our Fund I investors is a clear endorsement of our strategy and of the partnerships we have built since DELTA’s inception in 2021. We are also pleased to welcome a number of new institutional investors and look forward to building long-term relationships with them.”

John Luijs, Partner at DELTA Equity Partners

“Fund II allows us to continue executing the same focused strategy. We will remain committed to working closely with entrepreneurs to build strong, resilient and leading companies in attractive markets. With DELTA’s organisation and infrastructure now further developed, we can execute our strategy more efficiently and we expect to announce the first Fund II investments soon.”

Niels van Aalten, Partner at DELTA Equity Partners

Схожие новости

#Наименование новостиТональностьИнформативностьДата публикации
1Lightspring Capital Partners Closes Fund II At $218.1 Million5614-07-2026
2Mighty Therapeutics Secures Up To $150 Million To Advance Mitochondrial Targeted Medicines5514-07-2026
3En Carta Diagnostics Raises €5 Million To Advance At-Home Molecular Diagnostics Platform5712-07-2026
4Moonfare Surpasses €4 Billion In AUM After Strong Half-Year Inflows5514-07-2026
5Draig Therapeutics Raises $65 Million Series B To Advance Neuropsychiatric Therapies0514-07-2026
6Singularity Raises $80 Million Series A At $400 Million Valuation To Deploy Air Defense At Scale5714-07-2026
7Hephae Energy Technology Raises $17.8 Million Series A To Commercialize Superhot Drilling Technology5713-07-2026
8Spartan Capital Secures $160 Million Senior Credit Facility To Expand SMB Funding5712-07-2026
9Prenetics Raises $1 Billion For IM8 Via General Catalyst’s Customer Value Fund0515-07-2026
10Spero Therapeutics Announces $105 Million Non-Recourse Non-Dilutive Financing Backed By Utebzi Milestones And Royalties0714-07-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 5. Источник: pulse2.com.